Clinical Trial Update: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy [Phase 4]

View source ↗

Summary

This document discusses a Phase 4 trial evaluating extended TARPEYO treatment beyond 9 months in adults with primary IgA nephropathy. The study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Tarpeyo (budesonide)

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: IgA Nephropathy | Phase 4 | Status: RECRUITING